The short version of lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-24. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
== Clinical significance == Clarifications of the mesenteric anatomy have facilitated a clearer understanding of diseases involving the mesentery, examples of which include malrotation and Crohn's disease (CD). In CD, the mesentery is frequently thickened, rendering hemostasis challenging. In addition, fat wrapping—creeping fat—involves extension of mesenteric fat over the circumference of contiguous gastrointestinal tract, and this may indicate increased mesothelial plasticity. The relationship between mesenteric derangements and mucosal manifestations in CD points to a pathobiological overlap; some authors say that CD is mainly a mesenteric disorder that secondarily affects the GI tract and systemic circulation. Thrombosis of the superior mesenteric vein can cause mesenteric ischemia also known as ischemic bowel. Mesenteric ischemia can also result from the formation of a volvulus, a twisted loop of the small intestine that when it wraps around itself and also encloses the mesentery too tightly can cause ischemia. The rationalization of mesenteric and peritoneal fold anatomy permits the surgeon to differentiate both from intraperitoneal adhesions—also called congenital adhesions. These are highly variable among patients and occur in several locations. Congenital adhesions occur between the lateral aspect of the peritoneum overlying the mobile component of the mesosigmoid and the parietal peritoneum in the left iliac fossa. During the lateral to the medial approach of mobilizing of the mesosigmoid, these must be divided first before the peritoneum proper can be accessed.
The puff adder (Bitis arietans) is responsible for more fatalities than any other African snake. This is due to a combination of factors, including its wide distribution, common occurrence, large size, potent venom that is produced in large amounts, long fangs, their habit of basking by footpaths and sitting quietly when approached. The venom has cytotoxic effects and is one of the most toxic of any vipers based on LD50 studies. The LD50 values in mice vary: 0.4–2.0 mg/kg IV, 0.9–3.7 mg/kg IP, 4.4–7.7 mg/kg SC. Mallow et al. (2003) gives a LD50 range of 1.0–7.75 mg/kg SC. Venom yield is typically between 100–350 mg, with a maximum of 750 mg. Brown (1973) mentions a venom yield of 180–750 mg. About 100 mg is thought to be enough to kill a healthy adult human male, with death occurring after 25 hours. In humans, bites from this species can produce severe local and systemic symptoms. Based on the degree and type of local effect, bites can be divided into two symptomatic categories: those with little or no surface extravasation, and those with hemorrhages evident as ecchymosis, bleeding and swelling. In both cases there is severe pain and tenderness, but in the latter there is widespread superficial or deep necrosis and compartment syndrome. Serious bites cause limbs to become immovably flexed as a result of significant hemorrhage or coagulation in the affected muscles. Residual induration, however, is rare and usually these areas completely resolve. The fatality rate depends on the severity of the bites and some other factors.
=== Kazakhstan === According to the jurisdiction of the Republic of Kazakhstan, the term deputy (Kazakh: депутат, romanized: deputat) is the main and widely used word to describe a member of parliament (Kazakh: парламент депутаты, romanized: parlament deputaty) as a whole, encompassing both the lower house Mäjilis and the upper house Senate. While senator is also used to interchangeably describe a member of the Senate, the word "deputy" is the inclusive and general term for all 120 members of the Parliament. The 98 deputies of the Mäjilis obtain their mandate through mixed-member majoritarian representation, with 29 deputies elected from single-member districts and 69 deputies from closed-list proportional representation. The Senate consists of 50 deputies, out of which 40 are indirectly elected by mäslihats (local assemblies), while the remaining 10 are appointed by the President and the Assembly of People.
=== Pharmacodynamics === 2C-T-36 has a Ki of 0.35 nM at the serotonin 5-HT2A receptor, and an EC50Tooltip half-maximal effective concentration of 4.1 nM at the serotonin 5-HT2A receptor and 7.3 nM at the serotonin 5-HT2C receptor, compared to 88 nM at the serotonin 5-HT2B receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT2A and 5-HT2C receptors and produces psychedelic-like responding in several different animal species. The interactions of 2C-T-36 with numerous other receptors and targets have also been described.
the act was of such a lewd character as to outrage public decency; this element constitutes the nature of the act, which has to be proved before the offence can be established, and the act took place in a public place and must have been capable of being seen by two or more persons who were actually present, even if they did not actually see it. The mens rea of this offence can be satisfied if the defendant intentionally does an act which outrages public decency, regardless of one's state of mind. Judge Peter Rook QC and Robert Ward suggest that obiter dicta in cases such as R v Thallman (1863) 9 Cox CC 388 indicate that the requirement of a "public place" may be falling out of favour, due to its vagueness and redundancy to the requirement for two potential witnesses. In R v Hamilton [2007] EWCA Crim 2062 an act of upskirting in public went undetected until a police search discovered indecent images. It was held that it was immaterial whether a person had actually seen the act, provided it was capable of being seen by at least two persons. Previous cases had all been seen, but this was held to be a matter of evidence, not an element of the offence.
Sources: en.wikipedia.org
Oganesson is a synthetic chemical element; it has symbol Og and atomic number 118. It was first synthesized in 2002 at the Joint Institute for Nuclear Research (JINR) in Dubna, near Moscow, Russia, by a joint team of Russian and American scientists. In December 2015, it was recognized as one of four new elements by the Joint Working Party of the international scientific bodies IUPAC and IUPAP. It was formally named on 28 November 2016. The name honors the nuclear physicist Yuri Oganessian, who played a leading role in the discovery of the heaviest elements in the periodic table. Oganesson has the highest atomic number and highest atomic mass of all known elements. On the periodic table of the elements it is a p-block element, a member of group 18, and the last member of period 7. Its only known isotope, oganesson-294, is highly radioactive, with a half-life of 0.7 ms. This half-life is too short for chemical studies. Because of relativistic effects, theoretical studies predict that it would be a solid at room temperature, and significantly reactive, unlike the other members of group 18 (the noble gases).
Phenelzine, sold under the brand name Nardil among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine family which is primarily used as an antidepressant and anxiolytic to treat depression and anxiety. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.
=== Auxotrophy-based methods to incorporate unnatural amino acids into proteins and proteomes === A large number of unnatural amino acids, which are similar to their canonical counterparts in shape, size and chemical properties, are introduced into the recombinant proteins by means of auxotrophic expression hosts. For example, methionine (Met) or tryptophan (Trp) auxotrophic Escherichia coli strains can be cultivated in a defined minimal medium. In this experimental setup it is possible to express recombinant proteins whose canonical Trp and Met residues are completely substituted with different medium-supplemented related analogs. This methodology leads to a new form of protein engineering, which is not performed by codon manipulation at the DNA level (e.g. oligonucleotide-directed mutagenesis), but by codon reassignments at the level of protein translation under efficient selective pressure. Therefore, the method is referred as selective pressure incorporation (SPI). No organism studied so far encodes other amino acids than the canonical twenty; two additional canonical amino acids (selenocysteine, pyrrolysine) are inserted into proteins by recoding translation termination signals. This boundary can be crossed by adaptive laboratory evolution of metabolically stable auxotrophic microbial strains. For example, the first clearly successful attempt to evolve Escherichia coli that can survive solely on the unnatural amino acid thieno[3,2-b]pyrrolyl) alanine as the only substitute for tryptophan was made in 2015.
Traditionally the inherited metabolic diseases were classified as disorders of carbohydrate metabolism, amino acid metabolism, organic acid metabolism, or lysosomal storage diseases. In recent decades, hundreds of new inherited disorders of metabolism have been discovered and the categories have proliferated. Following are some of the major classes of congenital metabolic diseases, with prominent examples of each class.
Sources: en.wikipedia.org
=== Pathways === Opinions differ about optimal screening and diagnostic measures, partly due to differences in population risks, cost-effectiveness considerations, and lack of an evidence base to support large national screening programs. The most elaborate regimen entails a random blood glucose test during a booking visit, a screening glucose challenge test around 24–28 weeks' gestation, followed by an OGTT if the tests are outside normal limits. If there is a high suspicion, a woman may be tested earlier. In the United States, most obstetricians prefer universal screening with a screening glucose challenge test. In the United Kingdom, obstetric units often rely on risk factors and a random blood glucose test. The American Diabetes Association and the Society of Obstetricians and Gynaecologists of Canada recommend routine screening unless the woman is low risk (this means the woman must be younger than 25 years and have a body mass index less than 27, with no personal, ethnic or family risk factors) The Canadian Diabetes Association and the American College of Obstetricians and Gynecologists recommend universal screening. The U.S. Preventive Services Task Force found there is insufficient evidence to recommend for or against routine screening, and a 2017 a Cochrane review found that there is not evidence to determine which screening method is best for women and their babies.
Straub continued to work on actin, and in 1950 reported that actin contains bound ATP and that, during polymerization of the protein into microfilaments, the nucleotide is hydrolyzed to ADP and inorganic phosphate (which remain bound to the microfilament). Straub suggested that the transformation of ATP-bound actin to ADP-bound actin played a role in muscular contraction. In fact, this is true only in smooth muscle, and was not supported through experimentation until 2001. The amino acid sequencing of actin was completed by M. Elzinga and co-workers in 1973. The crystal structure of G-actin was solved in 1990 by Kabsch and colleagues. In the same year, a model for F-actin was proposed by Holmes and colleagues following experiments using co-crystallization with different proteins. The procedure of co-crystallization with different proteins was used repeatedly during the following years, until in 2001 the isolated protein was crystallized along with ADP. However, there is still no high-resolution X-ray structure of F-actin. The crystallization of G-actin was possible due to the use of a rhodamine conjugate that impedes polymerization by blocking the amino acid cys-374. Christine Oriol-Audit died in the same year that actin was first crystallized but she was the researcher that in 1977 first crystallized actin in the absence of Actin Binding Proteins (ABPs). However, the resulting crystals were too small for the available technology of the time.
Antiprion drugs Antiretroviral drug (especially HAART for HIV) COVID-19 drug repurposing research CRISPR-Cas13 Discovery and development of CCR5 receptor antagonists (for HIV) Discovery and development of NS5A inhibitors List of antiviral drugs Monoclonal antibody
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.